Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZYN002 in pediatric 22q11.2 deletion syndrome
ACTRN12619000673145Phase 2Recruiting
- Sponsor
- Zynerba Pharmaceuticals
- Start
- Feb 2020
- Modality
- Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Zygel in Velocardiofacial syndrome (VCFS), sponsored by Zynerba Pharmaceuticals. Primary endpoint: Safety and tolerability of ZYN002. Started Feb 2020; status: recruiting.
02
Drugs
Zygel
03
Conditions
Velocardiofacial syndrome (VCFS)
Beyond the preview
Go deeper on ACTRN12619000673145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619000673145.